You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和譽(02256.HK)治療肝癌藥物獲內地藥監局臨牀II期試驗批準
阿思達克 10-19 08:26
和譽(02256.HK)公佈,其創新FGFR4抑制劑ABSK011與羅氏制PD-L1抗體阿替利珠單抗(Atezolizumab)的聯合用藥方案,已獲得中國國家藥監局(NMPA)臨牀II期試驗批件,即將開展針對FGF19陽性晚期或不可切除肝細胞癌患者的研究。 ABSK011是一款創新的口服FGFR4小分子抑制劑,由和譽醫藥獨立自主研發。約30%HCC患者中FGF19-FGFR4信號通路異常激活,從而促進腫瘤生長而導致肝癌。臨牀前研究表明ABSK011具有優良的活性、選擇性及其它理化特性。目前ABSK011的單藥肝細胞癌臨牀試驗在進行中。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account